List of Excipients in Branded Drug XIGDUO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	XIGDUO	dapagliflozin and metformin hydrochloride	0310-6270	ANHYDROUS LACTOSE
AstraZeneca Pharmaceuticals LP	XIGDUO	dapagliflozin and metformin hydrochloride	0310-6270	CARBOXYMETHYLCELLULOSE SODIUM
AstraZeneca Pharmaceuticals LP	XIGDUO	dapagliflozin and metformin hydrochloride	0310-6270	CELLULOSE, MICROCRYSTALLINE
AstraZeneca Pharmaceuticals LP	XIGDUO	dapagliflozin and metformin hydrochloride	0310-6270	CROSPOVIDONE
AstraZeneca Pharmaceuticals LP	XIGDUO	dapagliflozin and metformin hydrochloride	0310-6270	HYPROMELLOSE 2208

Xigduo Excipient Strategy, Formulation IP, Generic Risk, and Commercial Opportunities

Last updated: September 27, 2026

Xigduo combines dapagliflozin, an SGLT2 inhibitor, with extended-release metformin hydrochloride. In the United States, the product is marketed as Xigduo XR in four strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg [1]. The core commercial opportunity is not a new active ingredient. It is the supply, optimization, and regulatory qualification of excipients and manufacturing technologies that support dual-drug extended release, tablet robustness, dose flexibility, and lower-cost generic development.

The most relevant opportunities are controlled-release polymers, direct-compression systems, coating materials, co-processed excipients, continuous manufacturing, and formulation support for generic dapagliflozin/metformin extended-release tablets.

What is Xigduo and how is it formulated?

Xigduo contains dapagliflozin propanediol and metformin hydrochloride. Xigduo XR uses an extended-release metformin component while dapagliflozin is released for systemic absorption as an immediate-release drug component within the combination tablet [1].

Product	Active ingredients	Key dosage strengths	Dosage form
Xigduo XR, U.S.	Dapagliflozin and metformin hydrochloride	5/500 mg, 5/1,000 mg, 10/500 mg, 10/1,000 mg	Extended-release film-coated tablet
Xigduo, European markets	Dapagliflozin and metformin hydrochloride	Commonly 5/850 mg, 5/1,000 mg, 10/1,000 mg	Film-coated tablet
Farxiga/Forxiga	Dapagliflozin	5 mg and 10 mg	Immediate-release tablet
Generic opportunity	Dapagliflozin and metformin hydrochloride	Strengths must match the applicable reference product	Extended-release tablet

The formulation challenge is the coexistence of two drugs with different dose loads, physicochemical properties, and release requirements. Metformin hydrochloride is present at a high mass relative to dapagliflozin. The tablet must maintain mechanical strength, acceptable size, dose uniformity, dissolution performance, and stability across four strength combinations.

What excipients are used in Xigduo XR?

The U.S. prescribing information identifies inactive ingredients that include lactose anhydrous, microcrystalline cellulose, hypromellose, silicon dioxide, magnesium stearate, and film-coating components such as polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and colorants [1].

Because excipient composition can vary by manufacturing site, market, strength, and labeling revision, the applicable product label and regulatory filing control the precise composition. The commercial formulation architecture can be summarized as follows:

Excipient category	Representative material in the U.S. label	Likely function
Bulking agent	Anhydrous lactose	Tablet mass and compression support
Diluent and compaction aid	Microcrystalline cellulose	Compressibility, tablet structure
Release-controlling polymer	Hypromellose	Extended-release matrix or release control
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Film former	Polyvinyl alcohol	Protective and aesthetic coating
Opacifier	Titanium dioxide	Color and light protection
Plasticizer	Polyethylene glycol	Coating flexibility
Anti-adherent	Talc	Coating process performance
Colorant	Iron oxide or other permitted colorants	Strength identification and appearance

The most strategically important excipient is hypromellose because polymer grade, viscosity, particle size, substitution pattern, and loading can affect metformin release. Microcrystalline cellulose and lactose also influence tablet porosity, tensile strength, friability, and dissolution.

What excipient strategies are most relevant to Xigduo?

Controlled-release polymer optimization

Generic developers can pursue a polymer platform that reproduces the reference dissolution profile without copying a proprietary supplier grade or relying on a single raw-material source. Relevant variables include:

• Hypromellose viscosity and substitution grade
• Polymer particle-size distribution
• Polymer-to-drug ratio
• Matrix porosity
• Compression force
• Granulation endpoint
• Tablet hardness and friability
• Coating weight gain
• Dissolution-media sensitivity

The principal development risk is overfitting to one dissolution condition. Metformin extended-release products must be evaluated across multiple media, agitation speeds, pH conditions, and dose strengths. A polymer system that performs well in one medium can fail under another because of rapid hydration, erosion, dose dumping, or incomplete release.

Co-processed excipients

Co-processed microcrystalline cellulose, lactose, mannitol, starch, or silicified systems can improve flow and compression while reducing formulation complexity. The commercial value is greatest where a developer needs:

• Lower lubricant sensitivity
• Better high-dose tablet compression
• Reduced tablet weight
• Improved content uniformity
• Fewer granulation steps
• More consistent scale-up

A co-processed excipient may also support direct compression. The regulatory burden is higher when the excipient has no established compendial history or when its critical material attributes differ materially from the reference formulation.

Lactose-free and low-lactose alternatives

The U.S. reference formulation includes anhydrous lactose [1]. This creates an opportunity for lactose-free or low-lactose generic formulations using microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch derivatives, or co-processed systems.

The commercial opportunity is limited by performance requirements. A lactose substitute must preserve:

• Tablet tensile strength
• Metformin release behavior
• Dapagliflozin assay and content uniformity
• Moisture stability
• Compatibility with magnesium stearate
• Film-coating adhesion
• Bioequivalence

Replacing lactose may also alter tablet density and gastrointestinal hydration. Such a change can produce a new dissolution profile even when the active ingredients and polymer concentration remain unchanged.

Low-moisture processing

Dapagliflozin and metformin combination products benefit from controlled humidity during blending, granulation, compression, and packaging. A low-moisture process can reduce hydrolytic or physical stability risks, limit sticking, and improve coating consistency.

Commercial opportunities include:

• Dry granulation
• Roller compaction
• Low-residual-moisture excipient systems
• Desiccant-integrated packaging
• High-barrier blister films
• In-line moisture monitoring

A dry process may improve cost and throughput, but it can also increase segregation risk in a formulation containing a low-dose active ingredient alongside high-dose metformin.

What formulation patents protect Xigduo?

Xigduo’s protection is expected to involve several layers rather than a single excipient patent:

1. Dapagliflozin compound and crystalline-form patents.
2. Dapagliflozin pharmaceutical-composition patents.
3. Dapagliflozin/metformin combination patents.
4. Extended-release formulation and dosing patents.
5. Method-of-use patents covering type 2 diabetes and related cardiometabolic conditions.
6. Manufacturing and solid-form claims, where applicable.

The relevant patent scope must be separated from regulatory exclusivity. FDA approval of Xigduo XR does not mean that every excipient, polymer, or tablet process is independently patented. Conversely, a formulation patent can create a litigation risk even when the active-ingredient patent has expired.

Protection category	Relevance to an excipient supplier	Typical design-around path
Active-ingredient patent	Low for excipient substitution	Use after expiry or under a valid challenge
Combination patent	Moderate	Alter composition, dosage form, or claim-relevant parameters
Extended-release patent	High	Use a different polymer architecture or release mechanism
Method-of-use patent	Low for excipient selection	Label and regulatory strategy
Manufacturing patent	Moderate to high	Use an alternative granulation, compression, or coating process
Supplier know-how	High commercially, not necessarily patent-based	Qualify a second source or develop equivalent material

Patent status should be checked against the current FDA Orange Book and relevant national registers before a formulation launch. Patent expiration, pediatric extensions, terminal disclaimers, and litigation settlements can change the practical launch date [2].

When does Xigduo lose exclusivity?

Xigduo XR received FDA approval in 2014 [1]. The principal regulatory exclusivity period for dapagliflozin as a new chemical entity was separate from the later combination-product patent estate. Small-molecule exclusivity is not the same as patent protection and does not prevent all later applications once the exclusivity period ends.

The commercial launch date for a generic depends on:

• FDA-listed patents
• Paragraph IV certifications
• ANDA litigation
• Any 30-month stay
• Patent settlement terms
• First-filer status
• Regulatory approval timing
• Whether the generic is approved for all listed strengths

There is no biosimilar pathway for Xigduo because it is a small-molecule combination drug. Competitors would generally use an abbreviated new drug application, or ANDA, rather than a biosimilar application.

What is the Orange Book status of Xigduo XR?

The FDA Orange Book is the controlling source for listed patents and exclusivity associated with approved U.S. drug products [2]. Xigduo XR should be evaluated by product name, strength, application number, and reference-listed drug status.

For commercial diligence, the relevant Orange Book review should identify:

• Listed patents for Xigduo XR
• Expiration dates
• Pediatric exclusivity, if any
• Whether patents cover the combination, formulation, or method of use
• Whether a patent has a use code that can be carved out
• Whether all four strengths are covered equally
• Whether a later generic has been approved

An excipient supplier should not assume that a non-infringing polymer substitution eliminates all risk. A formulation patent may use functional or compositional claim language that reaches multiple excipient systems.

Which companies are challenging Xigduo patents?

Publicly available regulatory and litigation records must be reviewed for each ANDA applicant and patent certification. Generic manufacturers active in dapagliflozin and metformin products are the most likely participants, but the existence of a generic dapagliflozin product does not establish a challenge to every Xigduo XR patent.

The relevant legal records include:

• FDA Paragraph IV notices
• Hatch-Waxman complaints
• District court docket entries
• Federal Circuit decisions
• ANDA approval records
• Patent settlement filings

A generic applicant can challenge a patent by asserting invalidity, noninfringement, or unenforceability. It can also submit a Paragraph III certification and defer launch until patent expiry. A section viii statement may allow approval for non-patented uses if the listed method-of-use claim can be carved out.

What generic entry risks exist for Xigduo?

Generic entry risk is highest when the combination can be reproduced with conventional excipients and the required dissolution and bioequivalence standards are achievable without a complex device or delivery system. Xigduo XR is a tablet, which generally presents a lower technical barrier than an inhaled, injectable, implantable, or biologic product.

The main technical barriers are:

• High metformin drug loading
• Low-dose dapagliflozin uniformity
• Extended-release dissolution matching
• Strength proportionality
• Stability under humidity stress
• Tablet size
• Bioequivalence across strengths
• Potential patent claims directed to release architecture

A low-cost generic may use the same broad excipient classes while changing supplier, grade, ratio, or processing sequence. This makes excipient differentiation difficult unless the supplier offers measurable performance advantages.

What commercial opportunities exist for excipient suppliers?

High-value opportunities

Opportunity	Commercial rationale	Development priority
High-performance hypromellose	Direct influence on metformin release	High
Co-processed direct-compression excipient	Reduces process steps and improves flow	High
Lactose-free diluent system	Supports differentiated generic positioning	Medium
Low-moisture excipient platform	Improves stability and manufacturing control	Medium
Functional coating system	Supports appearance, light protection, and robustness	Medium
Dual-source equivalent excipients	Reduces supply-chain concentration	High
Continuous-manufacturing formulation support	Improves throughput and process control	Medium
Analytical and dissolution services	Reduces ANDA development burden	High

The strongest commercial model is a qualified excipient platform supported by formulation data, not a commodity sale of lactose or magnesium stearate. Customers will value a supplier that can provide comparative dissolution data, scale-up support, regulatory documentation, and global supply continuity.

Manufacturing and IP barriers

Excipient suppliers face four practical barriers:

1. The reference formulation may use a proprietary grade or undocumented process parameter.
2. A polymer substitution can change dissolution and trigger bioequivalence risk.
3. Regulatory agencies may require extensive justification for excipient level changes.
4. Generic manufacturers may select the lowest-cost compendial material unless the supplier demonstrates a process advantage.

The supplier’s defensible position should therefore combine material specifications, process know-how, analytical methods, and documented performance across multiple strengths.

How does Xigduo compare with other diabetes combination products?

Product type	Formulation complexity	Excipient opportunity	Generic barrier
Dapagliflozin immediate-release tablet	Low to moderate	Direct compression, coating, flow	Moderate
Xigduo XR	Moderate to high	Release polymers, high-load compression	Moderate to high
Dapagliflozin/metformin immediate-release combination	Moderate	Blending, dose uniformity	Moderate
SGLT2/DPP-4 fixed-dose combination	Moderate	Low-dose uniformity, coating	Moderate
GLP-1 injectable	High	Device, container closure, sterile excipients	High
Biologic diabetes product	Very high	Stabilizers, buffers, container systems	Very high

Xigduo XR offers a more attractive excipient-development target than a conventional immediate-release tablet because the extended-release metformin component creates meaningful formulation sensitivity. It remains less technically protected than injectable or biologic products.

What is the revenue exposure and market opportunity?

AstraZeneca reports diabetes products within broader cardiovascular, renal, and metabolic categories rather than consistently disclosing standalone Xigduo revenue [3]. As a result, Xigduo-specific revenue exposure cannot be inferred reliably from company-level diabetes sales.

The commercial value for excipient companies comes from recurring volume across:

• Originator supply
• Authorized generics
• ANDA manufacturers
• Regional generic manufacturers
• Contract development and manufacturing organizations
• Dapagliflozin/metformin products outside the United States

The addressable market is broader than Xigduo itself because the same excipient platform can support other high-dose metformin extended-release products. A successful formulation system could be reused in metformin monotherapy, SGLT2 combination products, and other modified-release oral tablets.

What is the best excipient strategy for a Xigduo generic?

The preferred strategy is a multi-source, performance-based formulation platform:

1. Use a compendial hypromellose grade with documented viscosity and particle-size controls.
2. Develop a direct-compression or dry-granulation process to reduce moisture exposure.
3. Screen lactose-free and lactose-containing systems in parallel.
4. Optimize the formulation against all four U.S. strengths.
5. Establish discriminatory dissolution methods before pivotal bioequivalence batches.
6. Build a supplier-change protocol around critical material attributes.
7. Generate comparative data under accelerated and long-term stability conditions.
8. Review Orange Book patents before finalizing the commercial formulation.
9. Preserve a section viii strategy where method-of-use claims permit labeling carve-outs.
10. Use a second-source excipient package before commercial launch.

The winning supplier proposition is consistent release performance with lower manufacturing variability, not simply a lower excipient price.

Key Takeaways

• Xigduo XR is a dapagliflozin/metformin hydrochloride extended-release tablet marketed by AstraZeneca.
• The key formulation challenge is high-dose metformin extended release combined with low-dose dapagliflozin.
• Hypromellose, microcrystalline cellulose, lactose, silicon dioxide, magnesium stearate, and film-coating materials are the main excipient categories identified in the U.S. label.
• The strongest excipient opportunities are controlled-release polymers, co-processed direct-compression systems, low-moisture processing, and second-source qualification.
• Xigduo is a small-molecule product and faces generic, not biosimilar, competition.
• Patent risk can arise from combination, extended-release, method-of-use, manufacturing, and solid-form claims.
• FDA Orange Book review is required before assessing generic launch timing or formulation freedom to operate.
• Xigduo-specific revenue is not consistently disclosed, so commercial diligence should use product-level market data rather than AstraZeneca’s broader diabetes reporting.
• A formulation platform that works across all strengths and supports global regulatory filings offers the clearest commercial opportunity.

FAQs

Can lactose be removed from Xigduo XR without changing regulatory risk?

Yes, but the substitute must preserve dissolution, stability, tablet strength, assay, content uniformity, and bioequivalence. Removing lactose can create meaningful changes in tablet porosity and release behavior.

Is hypromellose the only polymer suitable for a Xigduo generic?

No. Other hydrophilic or matrix-forming polymers may be technically feasible, but each alternative requires formulation, dissolution, stability, and bioequivalence support. A different polymer may also affect patent and regulatory analysis.

Does a generic Xigduo tablet need to use the same excipients as the reference product?

No. Generic products generally may use different inactive ingredients if they meet applicable safety, quality, bioequivalence, and regulatory requirements. The formulation must still comply with patent and labeling constraints.

Can an excipient supplier patent a better Xigduo formulation?

Potentially. Patentable subject matter may include a novel composition, polymer ratio, release profile, manufacturing process, or stability-enhancing system. Patentability depends on novelty, inventive step, enablement, and claim scope.

Is Xigduo more attractive for excipient innovation than dapagliflozin alone?

Yes. The extended-release metformin component creates more formulation sensitivity than an immediate-release dapagliflozin tablet. That increases development complexity and creates more opportunities for differentiated excipient and process systems.

References

1. U.S. Food and Drug Administration. (2023). Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) tablets: Prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. AstraZeneca PLC. (2023). Annual report and Form 20-F 2023. AstraZeneca PLC.

4. European Medicines Agency. (n.d.). Xigduo: Product information. https://www.ema.europa.eu/